Dr. Mallika Dhawan is an oncologist who focuses on clinical trials and new treatment options for patients with advanced cancers in the UCSF Helen Diller Comprehensive Cancer Center’s Phase 1 Clinic. She also specializes in cancer prevention and screening for patients with hereditary cancer syndromes, like BRCA (linked to an increased risk of breast and ovarian cancers) or Lynch syndrome (a common cause of hereditary colon cancer). She specializes in determining optimal screening and imaging strategies for these patients. She is medical director of the Cancer Genetics and Prevention Program and Hereditary Cancer Program.

Dhawan earned her medical degree from the University of California, San Diego and completed her residency in internal medicine at Duke University. She completed a fellowship in oncology at UCSF.

In her free time, Dhawan enjoys being with her family and exploring the Bay Area.

  • Education

    UC San Diego School of Medicine, 2011

    UC San Diego, BS, Engineering, 2006

  • Residencies

    Duke University Medical Center, Internal Medicine, 2011

  • Fellowships

    UCSF, Oncology, 2017

  • Board Certifications

    Internal Medicine, American Board of Internal Medicine

    Medical Oncology, American Board of Internal Medicine

  • Academic Title

    Assistant Professor

Clinics I work with

Hereditary Cancer Clinic

Bakar Precision Cancer Medicine Building

See both of our San Francisco locations.

Cancer Genetics and Prevention Program

See all five of our Bay Area locations and learn about the program.

My reviews


Overall Experience
97 Reviews
Explained things in a way that was easy to understand
97 Reviews
Did the doctor pay attention to your concerns
97 Reviews
Gave easy to understand instructions about taking care of health problems or concerns
94 Reviews
Knew the important information about your medical history
97 Reviews
The provider showed respect for what you had to say
97 Reviews
The provider spent enough time with me
97 Reviews
Decorative Caduceus

Study of Olaparib (MK-7339) in Combination With Pembrolizumab (MK-3475) in the Treatment of Hom...

ORR is defined as the percentage of participants who have a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1. ...


Decorative Caduceus

Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous R...

ORR is defined as the percentage of participants who achieve a confirmed complete response ([CR]; disappearance of all target lesions) or partial response ([PR]: ≥30% decrease in the sum of diameters of target lesions) as assessed...


Decorative Caduceus

JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK ...

Safety and tolerability assessed by adverse events (AEs) and serious adverse events (SAEs)